ASH 2022 Conference Coverage
ECOG-ACRIN E1411: A Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab Based Induction Followed by Rituximab ± Lenalidomide Consolidation for MCL
By
ASH 2022 Conference Coverage
FEATURING
Mitchell Smith
By
ASH 2022 Conference Coverage
FEATURING
Mitchell Smith
Login to view comments.
Click here to Login